Evidence map›Paper›PMID 30368519›Full record

ArticleCell death & disease2018

CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo.

Neeraj K Aryal, Amanda R Wasylishen, Guillermina Lozano

Abstract read
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Generation of an Allelic Series at the Ahr Locus Using an Edited Recombinant Approach.Toxicological sciences : an official journal of the Society of Toxicology · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Neeraj K AryalDepartment of Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Amanda R WasylishenDepartment of Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Guillermina LozanoDepartment of Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. gglozano@mdanderson.org.ORCID http://orcid.org/0000-0001-8985-4886

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Base Pair MismatchCRISPR-Cas SystemsMutationAllelesAnimalsCRISPR-Associated Protein 9DEAD-box RNA HelicasesDNA End-Joining RepairEmbryo, MammalianGene EditingMiceMice, TransgenicRecombinational DNA RepairRibonuclease IIIRNA, Guide, CRISPR-Cas SystemsCRISPR-Associated Protein 9DEAD-box RNA HelicasesDicer1 protein, mouseRibonuclease IIIRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID30368519
PMCPMC6204134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.